|Availability||Out Of Stock|
Sitafloxacin tablets 50 mg(Gracevit, antibiotics, quinolone)
Brand : Japan Bioproducts
Product Code :
Availability : Out Of Stock
General information on Japanese Sitafloxacin tablets 50 mg (Gracevit, antibiotics, quinolone)
CURRENTLY NOT IN STOCK
Package details: 100 tablets
Manufacturer: Sawai Pharmaceutical Co., Ltd., Japan
Active ingredient: sitafloxacin hydrate (chemical formula C19H18ClF2N3O3)
Medical effect: Sitafloxacin tablets are effective for the treatment of the wide range of bacterial infections including following:
- respiratory tract infection,
- urinary tract infection,
- otolaryngological infection,
- dental/oral surgical infection.
Contraindications and precautions: do not use for pregnant, possibly pregnant or breastfeeding women. If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Sitafloxacin tablets 50 mg from Japan (Gracevit, antibiotics)
For adults, take 1 tablet 2 times a day, or 2 tablets once a day. If the effect is insufficient, the consulting doctor may increase the dosage up to 2 tablets 2 times a day.
How effective are Sitafloxacin tablets 50 mg from Japan (Gracevit, antibiotics)?
Sitafloxacin is a new-generation broad-spectrum fluoroquinolone antibacterial agent that works by inhibiting DNA replication in bacteria. It is effective for the treatment of the broad range of bacterial infections, including respiratory tract infection, urinary tract infection, cervicitis, otolaryngological infection and dental or oral surgical infection. The clinical safety profile of sitafloxacin has been characterized from 1,059 patients who participated in 10 clinical trials (D. L. Anderson. “Sitafloxacin hydrate for bacterial infections”. Drugs of Today (Barcelona), 2008, July, 44(7): 489-501).
Who should take Sitafloxacin tablets 50 mg from Japan?
Sitafloxacin is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, like methicillin-resistant staphylococci, Streptococcus pneumoniae and other streptococci with reduced susceptibility to levofloxacin and other quinolones. Sitafloxacin has also demonstrated activity against clinical isolates of Klebsiella pneumoniae (including about 67% of strains producing extended-spectrum, beta-lactamases and resistant to ciprofloxacin), Enterobacter cloacae, Pseudomonas aeruginosa with some activity against quinolone-resistant strains and Acinetobacter baumannii.